Ongoing research and innovative approaches, including ghrelin receptor modulators, stable PYY analogues, positive allosteric modulators for CCK, and advanced amylin analogues or DACRAs, showcase the potential for more effective and targeted anti‐obesity medications. Here, IAPP is linked to obesity due to melanocortin 4 receptor deficiency.